R&D channel feed

Scoop: Ab­b­Vie ter­mi­nates ear­ly-stage study of I-Mab's an­ti­body, an­oth­er clin­i­cal set­back in CD47 field

3 years ago
China

Up­dat­ed: Small cannabi­noid biotech says its CMO was hit with cy­ber­at­tack, re­sult­ing in clin­i­cal tri­al de­lays

3 years ago

Keytru­da hit with sec­ond PhI­II set­back this year as Mer­ck­'s block­buster flops cer­tain head and neck tri­al

3 years ago

Bris­tol My­ers vets tie up an­oth­er all-stock deal, lin­ing up clin­i­cal-stage on­col­o­gy pipeline

3 years ago
Deals

Gene ther­a­py for ovar­i­an can­cer fails PhI­II study — sink­ing biotech's shares

3 years ago
Cell/Gene Tx

MD­MA psy­chother­a­py tri­al put on pause af­ter Health Cana­da in­spec­tion

3 years ago
FDA+

Am­gen, GSK, Re­genxbio and oth­ers urge SCO­TUS to re­view 'dam­ag­ing' de­ci­sion on bio­med­ical patents

3 years ago
Law

As the pan­dem­ic high wanes, In­ovio chops head­count again while chas­ing Covid win

3 years ago
People

Lyn­parza fails a PhI­II test in col­orec­tal can­cer, cut­ting off big R&D av­enue for Mer­ck and As­traZeneca

3 years ago
Pharma

Ed­i­tas hires top Sanofi sci­en­tist for CMO as C-suite shuf­fle con­tin­ues

3 years ago

Sesen Bio paus­es blad­der can­cer drug work, of­floads eye dis­ease an­ti­bod­ies to Roche

3 years ago

Eliem de­lays a de­pres­sion tri­al, in­def­i­nite­ly post­pones an­oth­er af­ter blam­ing CMC is­sues for low drug ex­po­sure

3 years ago

Ky­owa Kirin pulls the plug on drug de­vel­op­ment for suc­ces­sor to Parkin­son's drug Nouri­anz

3 years ago

As Big Phar­ma los­es in­ter­est in new an­tibi­otics, in­fec­tions are on­ly grow­ing stronger

3 years ago

Texas biotech ex­pands R&D and man­u­fac­tur­ing ca­pa­bil­i­ties fol­low­ing Catal­ent part­ner­ship

3 years ago
Manufacturing

Up­dat­ed: Con­tra­Fect to ter­mi­nate PhI­II MR­SA an­tibi­ot­ic tri­al — stock cap­sizes

3 years ago

Dark-horse ALS play­er touts open-la­bel sur­vival da­ta af­ter mid-stage flop, with plat­form study due soon

3 years ago

No­vo Nordisk nabs pri­or­i­ty re­view vouch­er for $110M from Mar­i­nus as the biotech preps first drug launch

3 years ago
Financing
Deals

With failed NIH Covid-19 study, Hu­mani­gen CEO points to com­peti­tors' flops be­fore FDA nods

3 years ago
Coronavirus

Ama­zon joins Fred Hutch on clin­i­cal tri­al for per­son­al­ized can­cer vac­cine — re­port

3 years ago

With eyes on Keytru­da patent cliff, Mer­ck takes a $290M swing at prostate can­cer

3 years ago
Deals

Cur­tain-rais­er da­ta keep an­a­lysts on edge ahead of Am­gen’s big Lumakras/PD-1 com­bo read­out

3 years ago

De­spite tri­al dis­con­tin­u­a­tions, Rhythm’s ge­net­ic obe­si­ty drug ef­fec­tive in an­oth­er rare in­di­ca­tion 

3 years ago

'Ap­prov­abil­i­ty has been put to bed': Aldeyra says eye drop clears three dry eye sig­nals en route to FDA

3 years ago
First page Previous page 127128129130131132133 Next page Last page
A service from the Financial Times